1.866.339.0871         info@promab.com  info@promab.com

Chimeric-antigen receptors (CAR's), and specifically CAR-redirected T cells (CAR-T), have become an exceptionally promising field for immune-therapeutic interventions for cancers, and to date in clinical hematologic targets, response rates have been as high as 80-90%.
Promab will generate CAR's and CAR-T cells for your, from designing and developing antigen, through mouse monoclonal antibody generation and subsequent humanization, or direct human antibody cloning, to lentiviral transduction of T-cells with CAR's.